Genenta Science Plans to Acquire Majority Stake in ATC
Genenta Science intends to target majority ownership in companies with established operating profitability, typically generating up to approximately EUR 5M in EBITDA. In this context, Genenta plans to adopt the new corporate name of Saentra Forge with a new Nasdaq ticker symbol of (SAEN). Saentra Forge intends to pursue a strategy by acquiring targets at private-market valuations and integrating these companies under Saentra Forge. Through this integration, the company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility. Execution has commenced with ATC, a defense-sector company. Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received the required clearance under the Golden Power regulatory framework. ATC holds UAMA and SeRNI export-control licenses, NATO qualifications, and authorization from the Italian Ministry of Defense, and its platforms are used by special-forces units and include combat-proven systems. Genenta expects to fund a total of EUR 5.1M in several performance-driven tranches. ATC is projecting revenues of approximately EUR 4M in 2026, increasing to around EUR 9M by 2027. The company operates with a solid net cash position and no outstanding bank debt, reflecting a disciplined management structure. On the profitability side, ATC forecasts EBITDA of more than EUR 2M in 2026, with management expecting EBITDA to approximately double in 2027. In addition, ATC anticipates closing 2026 with a cash balance exceeding EUR 2M, and expects to further strengthen its liquidity position by ending 2027 with cash exceeding EUR 5M. At the core of the company's strategic configuration is the Praexidia Foundation, which has become a shareholder. The Praexidia Foundation is a private law foundation bringing together figures from Italian government institutions, the defense industry, and the armed forces. The company, the foundation, and Pierluigi Paracchi, founder and CEO, have entered into a shareholders' agreement that provides for consultation rights on corporate transactions and a renewable five-year lock-up. The company expects its cash, cash equivalents, and marketable securities at December 31, 2025, to be approximately $33M, compared to $17.7M at June 30, 2025. The increase is primarily due to the company's registered direct offering with certain institutional investors.
Get Free Real-Time Notifications for Any Stock
Analyst Views on GNTA

No data
About GNTA
About the author

Genenta Science Transitions to Defense Sector Consolidator
- Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
- Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
- Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
- Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.

Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
- Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
- Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
- Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
- Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.









